Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia

Future Oncology

Volumn 10, Issue 7, 2014, Pages 1147-1155

  Reagan, John L ^a   Castillo, Jorge J ^b  

^a RHODE ISLAND HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

chronic lymphocytic leukemia; immunotherapy; monoclonal antibodies; ofatumumab; untreated

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CASPASE; CD20 ANTIBODY; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; FLUDARABINE PHOSPHATE; IBRUTINIB; IDELALISIB; LENALIDOMIDE; MEMBRANE ANTIGEN; OFATUMUMAB; PENTOSTATIN; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG LEGISLATION; DRUG METABOLISM; HUMAN; PHAGOCYTOSIS; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT RESPONSE; UNITED STATES; ANIMAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; SURVIVAL RATE;

EID: 84903167043     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.73     Document Type: Article

References (47)

1. The Leukemia & Lymphoma Society. Facts 2013. www.lls.org/content/ nationalcontent/resourcecenter/freeeducat ion materials/generalcancer/pdf/facts. pdf
2. Chatterjee N, Hartge P, Cerhan JR et al. Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers. Cancer Epidemiol. Biomarkers Prev. 13, 1415-1421 (2004).
3. Mensah FK, Willett EV, Ansell P et al. Non-Hodgkin's lymphoma and family history of hematologic malignancy. Am. J. Epidemiol. 165, 126-133 (2007).
4. Castillo JJ, Dalia S, Pascual SK. Association between red blood cell transfusions and development of non-Hodgkin lymphoma: a meta-analysis of observational studies. Blood 116, 2897-2907 (2010).
5. Hallek M, Fischer K, Fingerle-Rowson G et al. Addition of rituximab to fudarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase 3 trial. Lancet 376, 1164-1174 (2010).
6. Bottcher S, Ritgen M, Fischer K et al. Minimal residual disease quantifcation is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J. Clin. Oncol. 30, 980-988 (2012).
7. Hillmen P, Skotnicki AB, Robak T et al. Alemtuzumab compared with chlorambucil as frst-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 25, 5616-5623 (2007).
8. Knauf WU, Lissichkov T, Aldaoud A et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 27, 4378-4384 (2009).
9. Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1750-1757 (2000).
10. Stilgenbauer S, Zenz T, Winkler D et al. Subcutaneous alemtuzumab in fudarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 27, 3994-4001 (2009).
11. Byrd JC, Furman RR, Coutre SE et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32-42 (2013).
12. Robak T, Dmoszynska A, Solal-Celigny P et al. Rituximab plus fudarabine and cyclophosphamide prolongs progression-free survival compared with fudarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 28, 1756-1765 (2010).
13. Goede V, Fischer K, Humphrey K et al. Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): fnal stage 1 results of the CLL11 (BO21004) Phase III trial. ASCO Meeting Abstracts 31, 7004 (2013).
14. Chanan-Khan A, Miller KC, Musial L et al. Clinical effcacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a Phase II st udy. J. Clin. Oncol. 24, 5343-5349 (2006).
15. Furman RR, Sharman JP, Coutre SE et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370(11), 997-1007 (2014).
16. Beers SA, Chan CHT, French RR et al. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin. Hematol. 47, 107-114 (2010).
17. Golay J, Lazzari M, Facchinetti V et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98, 3383-3389 (2001).
18. Huhn D, von Schilling C, Wilhelm M et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98, 1326-1331 (2001).
19. Hainsworth JD, Litchy S, Barton JH et al. Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: a Phase II Trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 21, 1746-1751 (2003).
20. Kennedy AD, Beum PV, Solga MD et al. Rituximab Infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J. Immunol. 172, 3280-3288 (2004).
21. Beum PV, Kennedy AD, Williams ME et al. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J. Immunol. 176, 2600-2609 (2006).
22. Cragg MS, Morgan SM, Chan HT et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101, 1045-1052 (2003).
23. Chan HTC, Hughes D, French RR et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into Triton X-100 insoluble membrane rafts. Cancer Res. 63, 5480-5489 (2003).
24. Byrd JC, Kitada S, Flinn IW et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99, 1038-1043 (2002).
25. Herter S, Herting F, Mundigl O et al. Preclinical activity of the Type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol. Cancer Ther. 12, 2031-2042 (2013).
26. Rafq S, Butchar JP, Cheney C et al. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J. Immunol. 190, 2702-2711 (2013).
27. Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104, 1793-1800 (2004).
28. Lemery SJ, Zhang J, Rothmann MD et al. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fudarabine and alemtuzumab. Clin. Cancer Res. 16, 4331-4338 (2010).
29. Teeling JL, Mackus WJ, Wiegman LJ et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177, 362-371 (2006).
30. Baig NA, Taylor RP, Lindorfer MA et al. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. J. Immunol. 192, 1620-1629 (2014).
31. Bologna L, Gotti E, Da Roit F et al. Ofatumumab is more effcient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J. Immunol. 190, 231-239 (2013).
32. Pawluczkowycz AW, Beurskens FJ, Beum PV et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol. 183, 749-758 (2009).
33. Okroj M, Eriksson I, Osterborg A, Blom AM. Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement. Med. Oncol. 30, 759 (2013).
34. Hörl S, Banki Z, Huber G et al. Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells. Haematologica 98, 1939-1947 (2013).
35. Coiffer B, Losic N, Rønn BB et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a Phase 1-2 study. Br. J. Haematol. 150, 58-71 (2010).
36. Struemper H, Sale M, Patel BR et al. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. J. Clin. Pharmacol. doi:10.1002/jcph.268 (2014) (Epub ahead of print).
37. Coiffer B, Lepretre S, Pedersen LM et al. Safety and effcacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a Phase 1-2 study. Blood 111, 1094-1100 (2008).
38. Wierda WG, Kipps TJ, Mayer J et al. Ofatumumab as single-agent CD20 immunotherapy in fudarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 28, 1749-1755 (2010).
39. Flinn IW, Harwin WN, Ward P et al. Phase II trial of ofatumumab (OFA) for older patients and patients who refuse fudarabine-based regimens with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Presented at: 54th ASH Annual Meeting and Exposition. Atlanta, GA, USA, 8-11 December 2012 (Abstract 719).
40. Wierda WG, Kipps TJ, Dürig J et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 117, 6450-6458 (2011).
41. Shanafelt T, Lanasa MC, Call TG et al. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer 119, 3788-3796 (2013).
42. Montillo M, Rossi D, Motta M et al. A Phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab (PCO) In older previously untreated chronic lymphocytic leukemia (CLL) patients. Presented at: 55th ASH Annual Meeting and Exposition. New Orleans, LA, USA, 7-10 December 2013 (Abstract 4177).
43. Keating MJ, Ferrajoli A, Konopleva M et al. Early ofatumumab treatment for high-risk, treatment-naive patients with chronic lymphocytic leukemia. Presented at: 55th ASH Annual Meeting and Exposition, New Orleans, LA, USA 7-10 December 2013 (Abstract 5307).
44. Hillmen P, Robak T, Janssens A et al. Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the Phase III study complement 1 (OMB110911). Presented at: 55th ASH Annual Meeting and Exposition. New Orleans, LA, USA, 7-10 December 2013 (Abstract 528)
45. UpToDate: Ofatumumab: drug information. www.uptodate.com/contents/ ofatumumab-drug-information?source = see-link
46. Kay NE, Geyer SM, Call TG et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows signifcant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109, 405-411 (2007).
47. Moreno C, Montillo M, Panayiotis P et al. A multicenter, Phase IV observational study of ofatumumab in chronic lymphocytic leukemia (CLL): a European Research Initiative On CLL (ERIC) study. Blood 122(21), Abstract 1645 (2013).